Antireticular cytotoxic serum (ACS / ATsS)

injection · 1934–1950

category:injection

delivery:Subcutaneous or intramuscular injection of a small therapeutic dose of animal serum (typically horse) previously sensitised against a homogenate of human spleen and bone marrow tissue and then bled three to five days later, in protocols set out in Bogomolets's monograph *The Prolongation of Life* (Duell, Sloan and Pearce, 1946).

price tier:elite

era:1934–1950

current status:historical

regulatory:withdrawn

SHORT PITCH (AS SOLD)

A serum prepared by sensitising an animal donor against human spleen and bone marrow tissue, given to humans in small doses to strengthen the reticular connective tissue and prolong life past one hundred, perhaps as long as one hundred and fifty years.

THE ACTUAL EVIDENCE

No controlled outcome trial has demonstrated a lifespan effect of ACS in humans. According to Joe Schwarcz's 20 September 2024 synthesis at the McGill Office for Science and Society, interest in ACS waned in the late 1940s after a grant to Harry Goldblatt (McGill MD 1916) supported a review of 3,500 patients treated at various centres that concluded the serum 'is not a cure for anything'. The bundle treats that 1940s evaluation as the load-bearing disconfirmation event for ACS as a clinical agent, with the caveat that a Goldblatt-authored primary publication of the 3,500-patient series is not indexed in NCBI and is therefore cited through Schwarcz's modern secondary account. The mechanism (small-dose stimulation of the reticuloendothelial system by xenogeneic anti-tissue serum) lacks contemporary support; the serum is no longer in recognised medical use.

PRACTITIONERS

Aleksandr Bogomolets

INGREDIENTS

Antireticular cytotoxic serum (ACS / ATsS)

CASES

bogomolets-acs-1934-1950

CLAIMS

Strengthening the reticular connective tissue with antireticular cytotoxic serum can let people live past one hundred, perhaps as long as one hundred and fifty years. untested
Antireticular cytotoxic serum, given in small therapeutic doses, stimulates the reticuloendothelial system and slows the deterioration of the connective tissue that holds the body together. untested
Antireticular cytotoxic serum is a broad therapeutic agent that accelerates fracture healing, supports postoperative recovery, and serves as an adjunct in the treatment of cancer and infection. refuted

SOURCES

The Prolongation of Life (1946)
The Life and Death of a Soviet-Era Search for Longevity (2024)

NOTES

Antireticular cytotoxic serum was the therapeutic application of Bogomolets’s connective-tissue theory of aging. It was prepared at the Kyiv Institute of Clinical Physiology under his direction in the late 1930s and 1940s, distributed across Soviet medicine for multiple indications (anti-aging, postoperative recovery, fracture healing, infection, and cancer adjunct), and presented to international medical audiences from 1934 onward. Its English-language framing for non-specialist readers was set by Bogomolets’s own 1946 Duell, Sloan and Pearce monograph The Prolongation of Life, published in the year of his death. The intervention is the Soviet-medical strand in the elite-targeted rejuvenation tradition that also produced Brown-Séquard’s self-injection (1889), Voronoff’s testicle grafts (1920s and 1930s), and Niehans’s lamb-fetal-cell therapy (1931 to 1971); ACS shares with those operations the developer-vendor-credentialing-author concentration of roles in a single individual, the absence of controlled outcome data, and the substitution of institutional and political endorsement for clinical evidence. After Bogomolets’s death in 1946 and the late-1940s Western evaluation reported by Schwarcz, ACS faded from the recognised medical pharmacopoeia.